Terminated trial tests unusual drug duo against tough breast cancers
NCT ID NCT03225547
Summary
This study tested whether combining an immunotherapy drug (pembrolizumab) with mifepristone could help control advanced breast cancers that lack the HER2 marker. It involved 24 patients with either triple-negative or hormone receptor-positive breast cancer that had spread or could not be surgically removed. The main goals were to see if tumors shrank and to check the safety of this drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.